• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

    0.6051 -0.0192 (-3.08%)
    Streaming Delayed Price Updated: 3:13 PM EST, Jan 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vistagen Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    News headline image
    VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    Why Did Vistagen Stock Tank 82% Today? ↗
    Via Stocktwits
    News headline image
    VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 13, 2025 ↗
     
    Via Benzinga
    News headline image
    VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
    From Robbins LLP
    Via GlobeNewswire
    News headline image
    VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
    From Robbins LLP
    Via Business Wire
    News headline image
    These stocks have an unusual volume in today's session ↗
    Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
    Via Chartmill
    News headline image
    On Friday, there are stocks with unusual volume. Let's take a look. ↗
    The trading volume of these stocks is deviating from the norm in today's session. 
    Via Chartmill
    News headline image
    On Thursday, there are stocks with unusual volume. Let's take a look. ↗
    Let's have a look at the stocks with an unusual volume in today's session. 
    Via Chartmill
    News headline image
    Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Appoints Nick Tressler as Chief Financial Officer
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
    From Vistagen
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Vistagen (VTGN) Q2 2026 Earnings Call Transcript ↗
    Vistagen (VTGN) Q2 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
    From Vistagen
    Via Business Wire
    News headline image
    Examining the Future: VistaGen Therapeutics's Earnings Outlook ↗
     
    Via Benzinga
    News headline image
    Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen to Participate in Stifel Healthcare Conference 2025
    From Vistagen
    Via Business Wire
    News headline image
    Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
    From Vistagen
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.